Trial Profile
A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients With B-Cell Acute Lymphoblastic Leukemia With Positive Minimal Residual Disease Before Any Hematopoietic Stem Cell Transplantation
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Mercaptopurine; Methotrexate; Prednisone; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 13 Dec 2022 Interim Results(n=51) evaluating the continuation of the study considering the slow accrual due to the Sars-COV2 pandemic, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 31 Dec 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Nov 2022.
- 03 Jun 2020 Planned primary completion date changed from 1 Nov 2022 to 1 Oct 2021.